Form 4: Seres Therapeutics Insider Trades: Brady Acquires Stock
Statement of Changes in Beneficial Ownership
Kelly Brady, Chief Operating Officer at Seres Therapeutics, acquired restricted stock units and sold shares to cover taxes.
Summary
- Kelly Brady, Chief Operating Officer, EVP of Seres Therapeutics, Inc., reported transactions on May 15, 2026, and May 18, 2026.
- On May 15, 2026, 180 shares of Common Stock were acquired (Transaction Code M).
- On May 18, 2026, 59 shares of Common Stock were disposed of at a price of $7.53 per share (Transaction Code S).
- Restricted Stock Units (RSUs) were also involved in transactions on May 15, 2026.
- RSUs representing 89 shares vested and settled, with a portion vesting quarterly thereafter.
- RSUs representing 91 shares vested and settled, with a portion vesting quarterly thereafter.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it primarily details routine insider transactions related to executive compensation and tax obligations, without strong indicators of positive or negative company performance.
Positives
- Acquisition of 180 shares of Common Stock by a key executive.
- Vesting and settlement of Restricted Stock Units, indicating progress in equity compensation plans.
Negatives
- Sale of 59 shares of Common Stock to cover taxes, which could indicate a need for liquidity or a decision to realize gains.
Future Outlook
The filing does not contain specific forward-looking statements or guidance. However, the ongoing vesting of Restricted Stock Units suggests continued equity-based compensation plans.
Industry Context
StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The activity reported by Kelly Brady, a senior executive, provides insight into internal confidence and compensation structures within the biotechnology sector, where equity awards are common.
Stakeholder Impact
- Shareholders: The acquisition of stock by an executive may be seen as a positive signal of confidence, while the sale to cover taxes is a routine event. The vesting of RSUs indicates ongoing compensation arrangements.
Next Steps
- Continued quarterly vesting and settlement of remaining Restricted Stock Units as per the terms outlined.
Key Dates
| Date | Description |
|---|---|
| 05/15/2026 | Earliest transaction date reported; acquisition of Common Stock and vesting/settlement of Restricted Stock Units. |
| 02/15/2024 | Initial vesting date for a portion of certain Restricted Stock Units. |
| 02/15/2025 | Initial vesting date for a portion of other Restricted Stock Units. |
| 05/18/2026 | Disposal of Common Stock to cover taxes. |
| 05/19/2026 | Date of signature for the filing. |
Keywords
Seres Therapeutics, MCRB, Form 4, Insider Trading, Stock Options, Restricted Stock Units, Executive Compensation, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.